Abstract
Hematopoietic stem cell transplantation (HSCT) has become the frontline therapy for patients with multiple myeloma (MM), and for young patients with primary MM, early autologous stem cell transplantation (ASCT) is a standard treatment. In the era of novel drugs, the application of new pharmaceutics in the consolidation and maintenance therapy before and after HSCT can improve the efficacy of HSCT. The novel agents pose a challenge to the status of HSCT in relapsed and refractory myeloma. This article summarizes the recent clinical studies of HSCT in the era of novel agents to clarify the role of HSCT in treatment of MM. Key words: Multiple myeloma; Hematopoietic stem cell transplantation; Drugs, investigational
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
